Intestinal Research

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies

Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink

Intest Res. 2017;15(4):475-486. Published online October 23, 2017
DOI: https://doi.org/10.5217/ir.2017.15.4.475

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies

Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink

Intestinal Research. 2017;15(4):475

Link1 Link2 Link3

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)

Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano

Intestinal Research. 2021;19(4):386-397

Link1

Link2 Link3

Efficacy and safety of ustekinumab in Russian bionaive patients with moderately to severely active ulcerative colitis: a subanalys is of global phase 3 induction and maintenance studies (UNIFI) up to 3 years

E. A. Belousova, R. A. Abdulkhakov, I. G. Bakulin, A. V. Kulyapin, A. V. Tkachev, Colleen Marano, Ye Miao

Koloproktologia. 2023;22(1):54-64

Link1

DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study

J Rosh, D Turner, A Griffiths, D Jacobstein, O Adedokun, L Padgett, N Terry, C O’Brien, J Hyams

Journal of Crohn's and Colitis. 2020;14(Supplement_1):S107-S108

Link1

Link2

1164 EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM UNISTAR, A PHASE 1 STUDY

Joel R. Rosh, Dan Turner, Anne M. Griffiths, Douglas Jacobstein, Omoniyi J. Adedokun, Lakshmi Padgett, Natalie A. Terry, Christopher D. O'Brien, Jeffrey S. Hyams

Gastroenterology. 2020;158(6):S-235-S-236

Link1 Link2

Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study

Joel R Rosh, Dan Turner, Anne Griffiths, Stanley A Cohen, Douglas Jacobstein, Omoniyi J Adedokun, Lakshmi Padgett, Natalie A Terry, Christopher O’Brien, Jeffrey S Hyams

Journal of Crohn's and Colitis. 2021;15(11):1931-1942

Link1

Link2

Link3

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

W Reinisch, R Panaccione, M Duijvestein, D Ceballos Santos, G Y Melmed, S Xuan, L Wegrzyn, G Levy, D Ilo, Y Sanchez Gonzalez

Journal of Crohn's and Colitis. 2023;17(Supplement_1):i672-i673

Link1

Link2

P519 Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials

S Friedrich, L Chua, X C Zhang

Journal of Crohn's and Colitis. 2023;17(Supplement_1):i646-i646

Link1

Link2

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis

R Panaccione, E B Collins, G Y Melmed, S Vermeire, S Danese, P D R Higgins, W Zhou, D Ilo, D Sharma, Y Sanchez Gonzalez, S T Wang

Journal of Crohn's and Colitis. 2022;16(Supplement_1):i037-i041

Link1

Link2

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marla C. Dubinsky, Keith Betts, Devrim Eren, Wenxi Tang, Lei Yin, Komal Gupte-Singh

Gastroenterology. 2022;162(7):S-602

Link1 Link2